Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey®)

Assessment Status Rapid Review Complete
Drug Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF)
Brand Odefsey®
Indication For the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml.
Assessment Process
Rapid review commissioned 28/06/2016
Rapid review completed 11/07/2016
Rapid review outcome Reimbursement Not Recommended

4th October 2016 – The NCPE has recommended reimbursement following a re-submission of updated clinical evidence.